Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART) : a multicentre, prospective, randomised, open-label, blinded-endpoint trial

Mackenzie, I S, Hawkey, C J, Ford, I, Greenlaw, N, Pigazzani, F, Rogers, A, Struthers, A D, Begg, A G, Wei, L, Avery, A J, Taggar, J S, Walker, A, Duce, S L, Barr, R J, Dumbleton, J S, Rooke, E D, Townend, J N, Ritchie, L D, MacDonald, T M, Ahmed, H, Arthur, P, Aziz, J, Barnes, L, Boyle, S, Brighton, T, Brown, M, Caulfield, M, Dawson, J, Denvir, M, Doney, A SF, Doshi, S, Dryburgh, M, Eddleston, M, Finlayson, J, Fuat, A, Furnace, J, Grieve, JW K, Guthrie, G, Ham, S, Isaard, E, Jennings, C, Johnson, R, Kerr, C, Khan, S, Krishnan, K, Long, S, Mackintosh, A, Macleod, M J, McCormack, T, Weir, C & ALL-HEART Study Group 2022, 'Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART) : a multicentre, prospective, randomised, open-label, blinded-endpoint trial', The Lancet, vol. 400, no. 10359, pp. 1195-1205. https://doi.org/10.1016/S0140-6736(22)01657-9